- Home
- GLPG vs SBLK Comparison
GLPG vs SBLK Comparison
Compare GLPG & SBLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- SBLK
- Stock Information
- Founded
- GLPG 1999
- SBLK 2006
- Country
- GLPG Belgium
- SBLK Greece
- Employees
- GLPG N/A
- SBLK N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- SBLK Marine Transportation
- Sector
- GLPG Health Care
- SBLK Consumer Discretionary
- Exchange
- GLPG Nasdaq
- SBLK Nasdaq
- Market Cap
- GLPG 2.1B
- SBLK 2.1B
- IPO Year
- GLPG 2005
- SBLK N/A
- Fundamental
- Price
- GLPG $32.02
- SBLK $19.21
- Analyst Decision
- GLPG Sell
- SBLK Strong Buy
- Analyst Count
- GLPG 4
- SBLK 3
- Target Price
- GLPG $25.33
- SBLK $23.00
- AVG Volume (30 Days)
- GLPG 198.2K
- SBLK 1.1M
- Earning Date
- GLPG 10-29-2025
- SBLK 08-06-2025
- Dividend Yield
- GLPG N/A
- SBLK 1.04%
- EPS Growth
- GLPG N/A
- SBLK N/A
- EPS
- GLPG N/A
- SBLK 1.05
- Revenue
- GLPG $323,674,692.00
- SBLK $1,131,251,000.00
- Revenue This Year
- GLPG N/A
- SBLK N/A
- Revenue Next Year
- GLPG N/A
- SBLK $18.30
- P/E Ratio
- GLPG N/A
- SBLK $18.25
- Revenue Growth
- GLPG 5.43
- SBLK 2.95
- 52 Week Low
- GLPG $22.36
- SBLK $12.06
- 52 Week High
- GLPG $33.86
- SBLK $23.82
- Technical
- Relative Strength Index (RSI)
- GLPG 49.28
- SBLK 54.12
- Support Level
- GLPG $30.88
- SBLK $18.71
- Resistance Level
- GLPG $33.63
- SBLK $19.10
- Average True Range (ATR)
- GLPG 0.69
- SBLK 0.41
- MACD
- GLPG -0.02
- SBLK 0.00
- Stochastic Oscillator
- GLPG 41.45
- SBLK 60.84
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.